

BIBLIOGRAFÍA

1. DiLorenzo L, Trallesi M, Morelli D, Pompa A, Brunelli S, Buzzi MG, et al. Hemiparetic shoulder pain syndrome treated with deep dry needling during early rehabilitation: A prospective, open-label, randomized investigation. *Journal of Musculoskeletal Pain*. 2004; 12(2):25-34.
2. Fresno MJ, Mediavilla P, Mayoral O. Dry needling of myofascial trigger points for hypertonia spastica in incomplete spinal cord injuries. Report of two cases. *J Musculoske Pain*. [Abstract]. 2004; 12(9):75.
3. Herrero P, Mayoral O. A case study looking at the effectiveness of deep dry needling for the management of hypertonia. *J Musculoske Pain*. 2007; 15(2):55-60.
4. Trenado J, Herrero P, Ventura AL, García E, Jovellar P. Tratamiento de puntos gatillo miofasciales en el paciente con daño cerebral adquirido: un ensayo clínico. Comunicación. I Jornadas Nacionales de Dolor Miofascial. Toledo (España), 5-6 de Septiembre, 2009.
5. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. *Pain*. 2011; 152(9):1988-96.
6. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. *Neurology*. 2006; 67(21):241-15.
7. Behmand RA, Tucker T, Guyuron B. Single-site botulinum toxin type A injection for elimination of migraine trigger points. *Headache*. 2003; 43(10):1085-9.
8. Sdfairpour D, Jabbari B. Botulinum toxin A (Botox) for treatment of proximal myofascial pain in complex regional pain syndrome: two cases. *Pain Med*. 2010; 11(9):1415-8.
9. Ozcakilir Suheda, Sivrioglu K. Botulinum toxin in poststroke spasticity. *Clinical medicine and research*. 2007; 5(2):132-138.
10. Gerard E Francisco. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. *Ann Acad Med*. 2007; 36:22-30.
11. Bakheit AMO, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. *J Neurol Neurosurg Psychiatry*. 2004; 75:1558-1561.

12. Gugala B, Snela S. [Effectiveness of botulinum toxin in diminishing lower limbs spasticity in children with diplegic form of cerebral palsy]. *Chir Narzadow Ruchu Ortop Pd.* 2011; 76(2):91-5.
13. Tomášová Z, Hlustík, Král M, Otruba P, Herzig R, Krobot A, et al. Cortical activation changes in patients suffering from post-stroke arm spasticity an treated with botulinum toxin A. *J Neuroimaging.* 2011; 10.1111.
14. Béseler MR, Grao CM, Gil A, Martínez Lozano MD. Walking assessment with instrumented insoles in patients with lower limbs spasticity after botulinum toxin infiltration. *Neurología.* 2011
15. Molenaers G, Van Campenhout A, Fagard K, De Cat J, Desloovere K. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. *J Child Orthop.* 2010; 4(3):183-95.
16. Hong C-Z. Lidocaine injection versus dry needling to myofascial trigger point. The importance of the local twitch response. *Anm J Phys Med Rehabil* 1994 Jul-Aug;73 (4):256-63.
17. Ays, Evcik D, Tur Bs. Comparison of injection methods in myofascial pain syndrome: a randomized controlled trail. *Clin Rheumatol.* 2010; 29(11):19-23.
18. Ga H, Choi JH, Park CH, Yoon HJ. Acupuncture needling versus lidocaine injection of trigger points in myofascial pain syndrome in elderly patients-a randomised controlled trial. *Acupunct Med.* 2007; 25(4): 130-6.
19. Venancio Rde A, Alencar FG, Zamperini C. Different substances and dry-needling injections in patients with myofascial pain and headaches. *Cranio.* 2008; 26(2):96-103.
20. Venancio Rde A, Alencar FG, Jr., Zamperini C. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches. *Cranio.* 2009; 27(1):46-53.
21. Cobb DB, Watson WA, Fernández MC. Botulism-like syndrome after injections of botulinum toxin. *Vet Hun Toxicol.* 2000; 42(3):163.
22. Partikian A, Mitchell WG. Iatrogenic botulism in a child with spastic quadriplegia. *J Child Neurol.* 2007; 22(10):1235-7.
23. Tilton AH. Injectable neuromuscular blockade in treatment of spasticity and movement disorders. *J Child Neurol.* 2003; 18(1):50-66.

24. Simons DG, Travell JG, Simons LS. Dolor y disfunción miofascial. El manual de los puntos gatillo. Mitad superior del cuerpo. 2 ed. Madrid: Editorial Médica Panamericana; 2002. p. 735-737.
25. Burke D. Spasticity as an adaptation to pyramidal tract injury. *Adv Neurol.* 1988; 47:401-23.
26. Sheean G. The pathophysiology of spasticity. *European Journal of Neurology.* 2002; 9(1):3-9.
27. Nielsen J.B., Crone C, Hultborn H. The spinal pathophysiology of spasticity from a basic science point of view. *Acta Physiol.* 2007; 189:171-180.
28. Gracies, J.M. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. *Muscle Nerve.* 2005; 31:535-551.
29. Dietz V, Sinkjaer T. Spastic movement disorder: impaired reflex function and altered muscle mechanics. *Lancet Neurol.* 2007; 6(8):725-33.
30. Shah J, Phillips T, Danoff J, Gerber L. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. *J. Appl Physiol.* 2005; 99:1977-1984.
31. Sherrington, C.S. Decerebrate rigidity, and reflex coordination of movements. *J Physiol.* 1898; 22:319-332.
32. Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. 1980; 30(12):1303-13.
33. Pandyan A, Gregoric M, Barnes MP, Wood D, Van Wijak, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. *Disabil Rehabil.* 2005; 27 (1-2):2-6.
34. Sheean G. Neurophysiology of spasticity. In Barner MP and Johnson GR, editors. *Upper motor neurone syndrome and spasticity: Clinical management and neurophysiology.* Cambridge: Cambridge University Press; 2001. p. 12-78.
35. Yueh-Ling Hsieh, PT, PhD, Li-Wei Chou, MD, MSd et al. Spinal cord mechanism involving the remote effects of dry needling on the irritability of myofascial trigger spots in rabbit skeletal muscle. *Arch Phys Med Rehabil.* 2011; 92 (7):1098-105.
36. Navarro J, Herrero P, Del Moral R, De Diego C, Marijuán P.C. Cordancia electroencefálica: aplicación a la técnica de Punción Seca DNHS® en pacientes con enfermedad cerebro vascular: estudio piloto.

37. Richard L. Lieber. Estructura del músculo esquelético, función y plasticidad. Bases fisiológicas de la fisioterapia. 2 ed. Editorial McGraw-Hill Interamericana de España. 2004. p. 33-38.
38. Bryan Kolb, Ian Q. Whishaw. Neuropsicología humana. Editorial: Médica Panamericana; 2006. Capítulo 9.
39. Espasticidad y punción seca: técnica DNHS[®]. I Jornadas Nacionales de Dolor Miofascial. ISBN 778-84-693-1708-2.
40. Acebes X, Udina E. Neurofisiología de la espasticidad. Evaluación clínica y tratamiento de la espasticidad. Madrid: Médica Panamericana; 2009. p. 1-16.
41. Audette JF, Wang F, Smith H. Bilateral activation of motor unit potentials with unilateral needle stimulation of active myofascial trigger points. Am J Phys Med Rehabil. 2004; 83(5):368-374.
42. Randolph J. Nudo, PhD, Plautz E.J, PhD, Frost SB, PhD. Role of adaptative plasticity in recovery of function after damage to motor cortex. Muscle Nerve. 2001; 24:1000-1019.
43. Gómez L. Bases neurales de la recuperación motora en las lesiones cerebrales. Revista mexicana de Neurociencia. 2001; 2(4):216-221.
44. Allison B, Elovic E. Spasticity. Diagnosis and Management. Editorial: Demos Medical Publishing; 2010. Capítulo 21.
45. Merlei JP, Eisenberg KE, Russell SD, Sanes J.R. Denervation supersensitivity in skeletal muscle; analysis with a cloned cDNA probe. The journal of cell fisiology. 1984; 99:332-335.
46. Streichert LC, Sargent PB. The role of acetylcholinesterase in denervation supersensitivity in the frog cardiac ganglion. Journal of Physiology. 1992; 445:249-260.
47. Prado M, Reis R, Prado V.F, De Mello MC, Gomez M, De Mello F. Neurochemistry International. 2002; 41:291-299.